



Association of genetic variants of *TMEM135* and *PEX5* in the peroxisome pathway with cutaneous melanoma-specific survival

Haijiao Wang^{1,2,3}, Hongliang Liu^{2,3}, Wei Dai⁴, Sheng Luo⁵, Christopher I. Amos⁶, Jeffrey E. Lee⁷, Xin Li⁸, Ying Yue¹, Hongmei Nan⁸, Qingyi Wei^{2,3,9}

¹Department of Gynecology Oncology, The First Hospital of Jilin University, Changchun, Jilin, China; ²Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA; ³Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA; ⁴Department of Dermatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China; ⁵Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC, USA; ⁶Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA; ⁷Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA; ⁸Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, Indianapolis, IN, USA; ⁹Department of Medicine, Duke University School of Medicine, Durham, NC, USA

Contributions: (I) Conception and design: Q Wei, H Wang; (II) Administrative support: Q Wei, Y Yue, H Nan; (III) Provision of study materials or patients: CI Amos, JE Lee, X Li, H Nan; (IV) Collection and assembly of data: H Wang, W Dai, H Liu; (V) Data analysis and interpretation: H Wang, H Liu, S Luo; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Hongmei Nan. Department of Epidemiology, Richard M. Fairbanks School of Public Health, Indiana University, R3-C216A, 980 W Walnut Street, Indianapolis, IN 46202, USA. Email: hnan@iu.edu; Dr. Qingyi Wei. Duke Cancer Institute, Duke University Medical Center and Department of Medicine, Duke School of Medicine, 905 S LaSalle Street, Durham, North Carolina 27710, USA. Email: qingyi.wei@duke.edu.

Background: Peroxisomes are ubiquitous and dynamic organelles that are involved in the metabolism of reactive oxygen species (ROS) and lipids. However, whether genetic variants in the peroxisome pathway genes are associated with survival in patients with melanoma has not been established. Therefore, our aim was to identify additional genetic variants in the peroxisome pathway that may provide new prognostic biomarkers for cutaneous melanoma (CM).

Methods: We assessed the associations between 8,397 common single-nucleotide polymorphisms (SNPs) in 88 peroxisome pathway genes and CM disease-specific survival (CMSS) in a two-stage analysis. For the discovery, we extracted the data from a published genome-wide association study from The University of Texas MD Anderson Cancer Center (MDACC). We then replicated the results in another dataset from the Nurse Health Study (NHS)/Health Professionals Follow-up Study (HPFS).

Results: Overall, 95 (11.1%) patients in the MDACC dataset and 48 (11.7%) patients in the NHS/HPFS dataset died of CM. We found 27 significant SNPs in the peroxisome pathway genes to be associated with CMSS in both datasets after multiple comparison correction using the Bayesian false-discovery probability method. In stepwise Cox proportional hazards regression analysis, with adjustment for other covariates and previously published SNPs in the MDACC dataset, we identified 2 independent SNPs (*TMEM135* rs567403 C>G and *PEX5* rs7969508 A>G) that predicted CMSS (P=0.003 and 0.031, respectively, in an additive genetic model). The expression quantitative trait loci analysis further revealed that the *TMEM135* rs567403 GG and *PEX5* rs7969508 GG genotypes were associated with increased and decreased levels of mRNA expression of their genes, respectively.

Conclusions: Once our findings are replicated by other investigators, these genetic variants may serve as novel biomarkers for the prediction of survival in patients with CM.

Keywords: Cutaneous melanoma (CM); peroxisome; single-nucleotide polymorphism (SNP); expression quantitative trait loci; melanoma-specific survival

Submitted Mar 02, 2020. Accepted for publication Nov 06, 2020.

doi: 10.21037/atm-20-2117

View this article at: <http://dx.doi.org/10.21037/atm-20-2117>

Introduction

Skin cancers, including cutaneous melanoma (CM), are among the most common cancers worldwide. In the United States, their incidence continues to rise dramatically (1), having doubled in the last 4 decades. In 2019, approximately 96,480 patients were diagnosed with CM in the United States, accounting for 5.5% of all new cancer cases. As the most lethal skin cancer, deaths from CM account for 1.2% of cancer-related mortality (2). Although Breslow thickness, ulceration, and the mitotic rate are considered to be important prognostic indicators, many primary CM cases unexpectedly metastasize after complete surgical resection (3); consequently, CM has the highest mortality rate among all skin cancers. Therefore, it is of great urgency to identify and better understand additional prognostic biomarkers that may provide CM patients with more appropriate and individualized treatment options.

CM is a multifactorial disease originating from melanocytes. Host factors, such as fair skin pigmentation, and environmental factors, such as ultraviolet radiation, can contribute to the development of CM (4). Studies have also shown that genetic susceptibility is involved in both the development and progression of CM (5,6). In recent genome-wide association studies (GWASs), genetic variants have been found to be associated with both risk and survival of CM (7). However, few of the identified genetic variants, particularly single-nucleotide polymorphisms (SNPs), were biologically functional, nor did these studies provide support for the biological plausibility of their findings. To identify truly functional variants, more sophisticated and combined analyses in the post-GWAS era are needed, including the combination of hypothesis-based pathway analysis, meta-analysis, and functional analysis.

Peroxisomes are ubiquitous and dynamic organelles that are involved in the metabolism of reactive oxygen species (ROS) and lipids (8,9). They also act as intracellular signaling platforms in inflammatory, redox, lipid, and innate immune signaling (10-13). Emerging studies suggest that peroxisomes play roles in aging, nonalcoholic fatty liver disease, and neurodegenerative disorders (14,15). Other studies have suggested that peroxisomes play an important role in the progression of several cancers, and

abnormal peroxisome metabolism is one of the established characteristics of cancer cells (16-19). However, few studies have investigated the role of peroxisomes in disease progression of CM, and little is known about the effect of genetic variation in the peroxisome pathway genes on the clinical outcomes of CM patients.

Given that some genetic variants are known to be associated with CM prognosis, identifying additional genetic variants in some specific signaling pathways may provide novel prognostic biomarkers of CM. Considering the importance of the peroxisome pathway in cancers, it is likely that genetic variants in peroxisome pathway genes are associated with survival in CM patients. Therefore, we tested this hypothesis by using genotyping datasets from 2 previously published GWASs.

We present the following article in accordance with the TRIPOD reporting checklist (available at <http://dx.doi.org/10.21037/atm-20-2117>).

Methods

Study populations

In the present study, we used the data of 858 patients from a CM GWAS conducted at The University of Texas MD Anderson Cancer Center (MDACC) (20) as a discovery dataset. Another GWAS of 409 CM patients from 2 Harvard University cohort studies, the Nurses Health Study (NHS) and the Health Professionals Follow-up Study (HPFS) (21), was used as a replication dataset. All the CM patients were non-Hispanic Whites. Informed consent was obtained from all patients. The access to the datasets used in the present study was approved by the Institutional Review Boards of the MDACC (No. LAB03-0048), Brigham and Women's Hospital (No. 2007-P-000616), and Harvard T.H. Chan School of Public Health (No. 2007-P-000616), and conducted in accordance with the Declaration of Helsinki (as revised in 2013).

The discovery dataset was requested from the Database of Genotypes and Phenotypes (dbGaP: <http://www.ncbi.nlm.nih.gov/gap>), with an accession number of phs000187.v1.p1 (6). Genotyping was performed with the Illumina HumanOmni-Quad_v1_0_B array (Illumina Inc, San

Diego, CA) and subsequent genome-wide imputation (imputation quality $r^2 \geq 0.8$) was performed with the MaCH software using sequencing data from the 1000 Genomes Project, phase I v2 CEU data (March 2010 release) (22). The replication dataset was generated with the Illumina HumanHap610 array, and genome-wide imputation (imputation quality $r^2 \geq 0.8$) was also performed with the MaCH software using sequencing data from the 1000 Genomes Project CEU data (March 2012 release) (23). Compared with the NHS/HPFS dataset, patients in the MDACC dataset had relatively complete clinical information, including age, sex, Breslow thickness, metastasis, mitotic rate, ulceration, and survival outcome, in addition to individual genotyping data, while patients in the NHS/HPFS replication dataset had information only for age, sex, and survival outcome, in addition to genotyping data.

Gene and SNP extraction

We selected 90 peroxisome pathway genes, according to the Kyoto Encyclopedia of Genes and Genomes (KEGG), BioCarta, Reactome, and Gene Ontology (GO) databases in the Molecular Signatures Database (<http://software.broadinstitute.org/gsea/msigdb/index.jsp>). Because females carry 2 copies of the X chromosome (males are hemizygous), and no standard statistics have been established for sex-specific analysis, genes on the X chromosome were excluded from further analyses. Finally, after the exclusion of 2 genes (*ABCD1* and *ACSL4*) on the X chromosome (Table S1), 88 genes located on the autosomes remained as candidate genes. SNPs within these 88 genes including 2 kb upstream and downstream were extracted from the MDACC GWAS dataset. The quality control criteria for genotyped and imputed SNPs were: (I) a minor allelic frequency (MAF) ≥ 0.05 ; (II) a genotyping success rate $\geq 95\%$; and (III) Hardy-Weinberg equilibrium (HWE) $P \geq 1 \times 10^{-5}$.

Statistical analysis

CM-specific survival (CMSS) was defined as the time from diagnosis with CM to CM-related death or the date of last follow-up. Multivariate Cox proportional hazards regression analysis was performed to assess associations between SNPs and CMSS with an additive model using the GenABEL package of R software. The Bayesian false-discovery probability (BFDP) approach was used, instead of the false discovery rate, for multiple testing correction

with a prior probability setting of 0.1 and an upper detected hazards ratio of 3 (24). Only SNPs with a BFDP value < 0.8 in both the discovery and replication datasets were chosen for further independent analysis with adjustment for clinical covariates and previously published 40 SNPs from the same MDACC GWAS dataset.

A meta-analysis was further performed using the results of the SNPs from both the discovery and replication datasets using PLINK 1.90. Cochran's Q statistic and the I^2 index were used to assess inter-study heterogeneity. A Cochran's Q test P value > 0.1 and $I^2 < 50\%$ indicated no substantial heterogeneity between 2 studies; in such cases, a fixed-effects model was employed. Otherwise, a random-effects model was used. Potential functions of the identified SNPs and those with high linkage disequilibrium (LD) ($r^2 \geq 0.8$) were predicted by RegulomeDB (<http://www.regulomedb.org/>) and HaploReg4.1 (25). Additionally, Haploview v4.2 (26) was applied to construct a Manhattan plot, and LocusZoom (27) was used to produce regional association plots. A Kaplan-Meier curve was used to estimate survival function, and log-rank tests were performed to compare the effects of different genotypes on CMSS. To estimate the prediction accuracy of the model with demographic variables and the identified SNPs, time-dependent receiver operating characteristic (ROC) analysis was carried out with the "timeROC" package in R (28). Other statistical analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA), if not specified otherwise.

Results

Basic characteristics of the study populations

The basic characteristics of the 858 CM patients from the MDACC dataset and the 409 CM patients from the NHS/HPFS dataset have been described elsewhere (6). Briefly, the MDACC CM patients were enrolled in a hospital-based case-control study at a tertiary care center; they tended to be younger with more late-stage disease than patients undergoing follow-up in the NHS/HPFS cohort studies. In the MDACC study, patient age at diagnosis ranged between 17 and 94 years, with a mean age of 52.4 ± 14.4 years, and 57.8% (496/858) of the patients were males. The median follow-up time was 81.1 months, and at the last follow-up, 133 patients had died of various causes, including 95 (11.1%) who had died from CM. In the NHS/HPFS studies, patient age at diagnosis ranged between 34 and 87 years, with a mean age of 61.1 ± 10.8 years, and 33.7% (138/409) of




Figure 1 Study workflow for SNPs in the peroxisome pathway. AUC, area under the receiver operating characteristic curve; BFDP, Bayesian false-discovery probability; CMSS, cutaneous melanoma-specific survival; GWAS, genome wide association study; HWE, Hardy-Weinberg equilibrium; HPFS, Health Professionals Follow-up Study; MAF, minor allele frequency; MDACC, The University of Texas MD Anderson Cancer Center; NHS, the Nurse Health Study; *PEX5*, peroxisomal biogenesis factor 5; ROC, receiver operating characteristic; SNP, single nucleotide polymorphism; *TMEM135*, transmembrane protein 135.

the patients were males. The median follow-up time was 179.0 months, which was considerably longer than that of the MDACC study. However, the mortality rate of CM in the NHS/HPFS studies was 11.7% (48/409), which was similar to that in the MDACC patients.

Multivariate analyses of the associations between SNPs in the peroxisome pathway genes and CMSS

As summarized in the study flowchart shown in *Figure 1*, we extracted 1,215 genotyped and 7,182 imputed SNPs in the peroxisome pathway genes from the MDACC dataset. Associations between these SNPs and CMSS were evaluated through multivariate Cox proportional hazards regression analysis with adjustment for age, sex, regional/distant metastasis, Breslow thickness, ulceration, and the mitotic rate. In the single-locus analysis of these 8,397 SNPs, 332 were found to be significantly associated with CMSS at $P < 0.05$ in an additive genetic model, and after multiple testing correction, 227 SNPs, with BFDP < 0.8 , remained statistically noteworthy; these 227 SNPs were then replicated in the NHS/HPFS dataset (*Figure S1A*). After multivariate

Cox regression analysis with adjustment for age and sex in the NHS/HPFS dataset (*Figure S1B* and *Table S2*), 27 SNPs in 4 genes, with $P < 0.05$ and BFDP < 0.8 , remained significantly associated with CMSS. Among the 27 SNPs, there were 16 in *TMEM135* (transmembrane protein 135), 7 in *ACOX2* (acyl-CoA oxidase 2), 3 in *PEX5* (peroxisomal biogenesis factor 5), and 1 in *RAB8B* (member RAS oncogene family). In the subsequent meta-analysis, these 27 SNPs remained significantly associated with CMSS, with no heterogeneity observed across the 2 datasets (*Table 1*).

Genetic variants in the peroxisome pathway genes as independent predictors of survival

To further identify the independent predictors for CMSS survival, initial stepwise multivariate Cox regression analyses were performed to assess the effects of the 27 replicated SNPs on the survival of CM patients. These analyses were performed in the MDACC dataset only, because the NHS/HPFS dataset did not have the same detailed genotyping data and clinical covariates. Four SNPs in 4 genes remained statistically significantly associated

Table 1 Identification of 27 significant and replicated survival-associated SNPs in the peroxisome pathway genes

SNP	Allele ^a	Gene	Discovery-MDACC (n=858)				Validation-NHS/HPFS (n=409)				Combined-Meta-analysis (n=1,267)			
			EAF	HR (95% CI)	P ^b	BFDP	EAF	HR (95% CI)	P ^c	BFDP	P _{het}	I ²	HR (95% CI)	P ^d
rs117285370*	C>T	RAB8B	0.05	2.40 (1.37–4.22)	0.002	0.337	0.06	1.95 (1.03–3.69)	0.039	0.788	0.632	0	2.19 (1.44–3.34)	2.63×10 ⁻⁴
rs7969508*	A>G	PEX5	0.30	1.43 (1.04–1.97)	0.029	0.780	0.24	1.86 (1.23–2.81)	0.003	0.362	0.325	0	1.58 (1.22–2.03)	4.14×10 ⁻⁴
rs7969635	A>G	PEX5	0.30	1.43 (1.04–1.97)	0.029	0.780	0.24	1.86 (1.23–2.81)	0.003	0.362	0.325	0	1.58 (1.22–2.03)	4.14×10 ⁻⁴
rs7969751	A>T	PEX5	0.30	1.43 (1.04–1.97)	0.029	0.780	0.24	1.86 (1.23–2.81)	0.003	0.362	0.325	0	1.58 (1.22–2.03)	4.14×10 ⁻⁴
rs6807633*	C>T	ACOX2	0.09	1.65 (1.04–2.60)	0.032	0.763	0.08	2.10 (1.17–3.76)	0.013	0.628	0.524	0	1.81 (1.26–2.59)	0.001
rs6790046	G>A	ACOX2	0.09	1.65 (1.04–2.60)	0.032	0.763	0.09	1.82 (1.17–2.85)	0.008	0.597	0.631	0	1.77 (1.23–2.53)	0.002
rs9790147	C>G	ACOX2	0.09	1.65 (1.04–2.60)	0.032	0.763	0.08	2.10 (1.17–3.76)	0.013	0.628	0.524	0	1.81 (1.26–2.59)	0.001
rs9789958	G>A	ACOX2	0.09	1.65 (1.04–2.60)	0.032	0.763	0.09	1.89 (1.04–3.40)	0.035	0.767	0.721	0	1.74 (1.21–2.49)	0.001
rs9647382	A>G	ACOX2	0.09	1.65 (1.04–2.60)	0.032	0.763	0.08	2.10 (1.17–3.76)	0.013	0.628	0.524	0	1.81 (1.26–2.59)	0.001
rs76039946	G>A	ACOX2	0.09	1.64 (1.04–2.59)	0.033	0.775	0.08	1.97 (1.08–3.59)	0.028	0.740	0.634	0	1.75 (1.22–2.52)	0.002
rs113351358	C>T	ACOX2	0.09	1.64 (1.04–2.59)	0.033	0.775	0.08	1.97 (1.08–3.59)	0.028	0.740	0.634	0	1.75 (1.22–2.52)	0.002
rs567403*	C>G	TMEM 135	0.10	1.61 (1.03–2.51)	0.036	0.782	0.07	1.97 (1.03–3.74)	0.040	0.782	0.613	0	1.72 (1.19–2.48)	0.004
rs542279	C>T	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs631930	G>A	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs520718	C>T	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs35707386	G>T	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.06	2.48 (1.31–4.69)	0.005	0.492	0.269	18.24	1.85 (1.28–2.66)	9.71×10 ⁻⁴
rs556724	G>A	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs605658	T>C	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs618159	A>G	TMEM 135	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴

Table 1 (continued)

Table 1 (continued)

SNP	Allele ^a	Gene	Discovery-MDACC (n=858)				Validation-NHS/HPFS (n=409)				Combined-Meta-analysis (n=1,267)			
			EAF	HR (95% CI)	P ^b	BFDP	EAF	HR (95% CI)	P ^c	BFDP	P _{het}	I ²	HR (95% CI)	P ^d
rs2847352	T>A	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs498059	A>G	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs578116	G>A	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs482944	G>A	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs34782550	T>C	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs34806361	A>G	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs500725	A>G	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴
rs493708	C>T	<i>TMEM135</i>	0.10	1.60 (1.03–2.50)	0.038	0.793	0.07	2.57 (1.38–4.78)	0.003	0.386	0.224	32.46	1.88 (1.31–2.70)	6.24×10 ⁻⁴

^a, reference allele/effect allele; ^b, adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in the additive model; ^c, adjusted for age and sex in the additive model; ^d, meta-analysis in the fix-effects model. SNPs with * remained statistically significantly in independent analysis. SNP, single-nucleotide polymorphism; MDACC, MD Anderson Cancer Center; NHS, the Nurse Health Study; HPFS, the Health Professionals Follow-up Study; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval; BFDP, Bayesian false-discovery probability; Phet, P value for heterogeneity by Cochran's Q test; *ACOX2*, acyl-CoA oxidase 2; *PEX5*, Peroxisomal Biogenesis Factor 5; *TMEM135*, transmembrane protein 135; *RAB8B*, member RAS oncogene family.

with CMSS in the presence of covariates (i.e., age, sex, Breslow tumor thickness, regional/distant metastasis, tumor cell mitotic rate, and ulceration of tumors). These SNPs were *ACOX2* rs6807633 (imputed), *TMEM135* rs567403 (imputed), *PEX5* rs7969508 (genotyped), and *RAB8B* rs117285370 (imputed). Finally, following adjustment for the 40 additional previously published survival-associated SNPs with the same MDACC GWAS dataset, we found that 2 SNPs (*TMEM135* rs567403 C>G and *PEX5* rs7969508 A>G) remained significant (P=0.003 and 0.031, respectively) for further analysis (Table 2).

As shown in Table 3, in the MDACC dataset, the effects of the *TMEM135* rs567403 G and *PEX5* rs7969508 G alleles on the survival of CM patients were statistically significant (trend test: P=0.036 and 0.030, respectively), and similar results were observed in the NHS/HPFS studies (trend test: P=0.040 and 0.004, respectively) as well as in their combined dataset (trend test: P=0.023 and 0.001, respectively). We then depicted these associations by

using Kaplan-Meier survival curves (Figure 2A,B,C,D,E,F). Regional association plots were also generated to display the LD between the identified SNPs and those in *TMEM135* and *PEX5*, including the 50 kb regions flanking these 2 genes (Figure S2A,B).

Combined genotype analyses of the 2 independent SNPs

To assess the joint effect of the 2 independent SNPs on CMSS, we further combined the risk genotypes of *TMEM135* rs567403 CG+GG and *PEX5* rs7969508 AG+GG into a genetic score as the number of risk genotypes (NRG), and categorized all the patients into 3 groups with 0, 1, and 2 risk genotypes. The trend test showed that a higher NRG was associated with a progressively worse survival in the MDACC dataset in a dose-response manner (P=0.002), as well as in the NHS/HPFS dataset (P=0.003) and the combined dataset (P=0.0003), with adjustments for the available covariables (Table 3). Next, we further dichotomized

Table 2 Predictors of CMSS obtained from the stepwise Cox proportional hazards regression analysis with adjustment for the published 40 survival-associated SNPs in the same MDACC dataset

Parameter ^a	Category ^b	Frequency	HR (95% CI) ^a	P ^a	HR (95% CI) ^c	P ^c
Age	≤50/>50	371/487	1.02 (1.00–1.04)	0.018	1.05 (1.03–1.07)	<0.0001
Sex	Female/male	362/496	1.48 (0.93–2.36)	0.100	1.15 (0.68–1.93)	0.610
Regional/distant metastasis	No/yes	709/149	4.04 (2.61–6.26)	<0.0001	13.71 (7.38–25.47)	<0.0001
Breslow thickness(mm)	≤1/>1	347/511	1.18 (1.12–1.25)	<0.0001	1.26 (1.17–1.36)	<0.0001
Ulceration	No/yes	681/155	2.96 (1.91–4.61)	<0.0001	4.53 (2.64–7.76)	<0.0001
Mitotic rate (mm ²)	≤1/>1	275/583	2.46 (1.21–4.98)	0.013	2.14 (0.95–4.79)	0.065
<i>TMEM135</i> rs567403 C>G	CC/CG/GG	693/154/11	1.77 (1.13–2.77)	0.013	2.31 (1.34–3.97)	0.003
<i>PEX5</i> rs7969508 A>G	AA/AG/GG	406/388/64	1.45 (1.05–2.00)	0.023	1.57 (1.04–2.37)	0.031

^a, Stepwise Cox analysis included age, sex, regional/distant metastasis, Breslow thickness, ulceration, mitotic rate and 27 replicated SNPs; ^b, the “category/” was used as the reference; ^c, adjustment for 40 previously published survival-associated SNPs in the same MDACC dataset. CMSS, cutaneous melanoma-specific survival; MDACC, The University of Texas MD Anderson Cancer Center; HR, hazards ratio; CI, confidence interval; *PEX5*, Peroxisomal Biogenesis Factor 5; *TMEM135*, transmembrane protein 135.

the NRG score into 2 groups: low-risk (0-1 risk genotype) and high-risk (2 risk genotypes). We found that patients in the high-risk group had a higher CM-death risk in the MDACC dataset (HR =2.39, 95% CI: 1.37–4.19, P=0.002) and the NHS/HPFS dataset (HR =1.97, 95% CI: 1.16–6.55, P=0.022), as well as in the combined dataset (HR =2.17, 95% CI: 1.36–3.45, P=0.001), compared to those in the low-risk group (Table 3). These associations were also depicted by Kaplan-Meier curves (Figure 2G,H,I).

Stratified analyses for the effect of combined risk genotypes on CMSS

In the previous analysis we found that patients in the high NRG score group showed a substantially greater risk of CM-related death in the presence of the available clinical variables. The risk was more evident in the subgroup aged ≤50, male patients, patients with ulceration or late-stage disease, and those with a tumor cell mitotic rate >1/mm² in the MDACC dataset, as well as in the subgroup aged >50 and female patients in the NHS/HPFS dataset. However, no interactions were found (Table S3).

ROC curve and area under the curve (AUC) for prediction of CMSS

We further assessed the predictive effect of the 2 independent SNPs on CMSS using the time-dependent AUC of the ROC curve. The ROC of the 5-year CMSS

showed that the inclusion of the 2 identified SNPs only improved the predictive performance of the models including clinical variables without and with risk genotypes by 1.6% in the MDACC dataset (AUC =65.88% vs. 67.48%, P=0.336) (Figure S3A,B). However, we observed that the model with age, sex, and genetic variants had a better performance than those only including demographic variables in the NHS/HPFS dataset (54.05% vs. 70.88%, P=0.003) (Figure S3C,D) and in the combined dataset (AUC =63.6% vs. 67.61%, P=0.073) (Figure S3E,F).

Functional predictions of the 2 independent SNPs

Functional prediction by RegulomeDB showed that *TMEM135* rs567403 C>G and *PEX5* rs7969508 A>G had RegulomeDB scores of 5 and 1f, respectively, and also indicated that these SNPs might be located at DNase I regulating sites or transcription factor binding sites. We further searched for SNPs with high LD ($r^2 \geq 0.8$) with these 2 independent SNPs and made functional predictions by using HaploReg. We found that *TMEM135* rs567403 C>G might disrupt or change the motifs of Dox4 and Irf, whereas *PEX5* rs7969508 A>G, located in DNase I hypersensitive sites, may be a marker of promoter histone and enhancer histone in embryonic stem cell-derived tissue (ESDR), and may have a high linear correlation with mRNA expression of its corresponding gene *PEX5* (Table S4). We further assessed the potential functions of these 2 independent SNPs by using data from the ENCODE

Table 3 Associations between two independent SNPs in the peroxisome pathway genes and CMSS of the patients in the MDACC dataset, the NHS/HPFS dataset and the combined dataset

Genotype	MDACC (n=858)				NHS/HPFS (n=409)				MDACC + NHS/HPFS (n=1,267)			
	All	Death (%)	HR (95% CI) ^a	P ^a	All	Death (%)	HR (95% CI) ^b	P ^b	All	Death (%)	HR (95% CI) ^c	P ^c
<i>TMEM135</i> rs567403 C>G												
CC	693	72 (10.39)	1.00		357	38 (10.64)	1.00		1,050	110 (10.48)	1.00	
CG	154	22 (14.29)	1.71 (1.04–2.78)	0.035	50	9 (18.00)	1.71 (0.83–3.53)	0.149	204	31 (15.20)	1.55 (1.04–2.31)	0.031
GG	11	1 (9.09)	1.71 (0.23–12.68)	0.602	2	1 (50.00)	9.66 (1.28–72.77)	0.028	13	2 (15.38)	1.88 (0.46–7.69)	0.379
Trend test				0.036				0.040				0.023
CG+GG	165	23 (13.94)	1.71 (1.05–2.78)	0.032	52	10 (19.23)	1.86 (0.93–3.73)	0.081	217	33 (15.21)	1.56 (1.06–2.32)	0.024
<i>PEX5</i> rs7969508 A>G												
AA	406	38 (9.36)	1.00		236	20 (8.47)	1.00		642	58 (9.03)	1.00	
AG	388	48 (12.37)	1.63 (1.05–2.55)	0.031	148	21 (14.19)	1.74 (0.94–3.21)	0.079	536	69 (12.87)	1.51 (1.07–2.15)	0.020
GG	64	9 (14.06)	1.73 (0.79–3.78)	0.170	25	7 (28.00)	3.59 (1.52–8.52)	0.004	89	16 (17.98)	2.25 (1.29–3.92)	0.004
Trend test				0.030				0.004				0.001
AG+GG	452	57 (12.61)	1.65 (1.07–2.53)	0.023	173	28 (16.18)	2.00 (1.12–3.55)	0.019	625	85 (13.60)	1.61 (1.16–2.25)	0.005
Number of combined risk genotypes ^d												
0	329	30 (9.12)	1.00		205	16 (7.80)	1.00		534	46 (8.61)	1.00	
1	441	50 (11.34)	1.45 (0.90–2.32)	0.126	183	26 (14.21)	1.90 (1.02–3.55)	0.043	624	76 (12.18)	1.48 (1.02–2.13)	0.037
2	88	15 (17.05)	2.96 (1.57–5.57)	0.008	21	6 (28.57)	3.92 (1.52–10.12)	0.005	109	21 (19.27)	2.72 (1.62–4.56)	0.0002
Trend test				0.002				0.003				0.0003
0–1	770	80 (10.39)	1.00		388	42 (10.82)	1.00		1,158	122 (10.54)	1.00	
2	88	15 (17.05)	2.39 (1.37–4.19)	0.002	21	6 (28.57)	2.76 (1.16–6.55)	0.022	109	21 (19.27)	2.17 (1.36–3.45)	0.001

^a, adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in the MDACC dataset; ^b, adjusted for age and sex in the NHS/HPFS dataset; ^c, adjusted for age and sex in the MDACC and NHS/HPFS combined dataset; ^d, risk genotypes included *TMEM135* rs567403 CG+GG and *PEX5* rs7969508 AG+GG. SNP, single-nucleotide polymorphism; CMSS, cutaneous melanoma-specific survival; MDACC, The University of Texas MD Anderson Cancer Center; NHS, the Nurse Health Study; HPFS, the Health Professionals Follow-up Study; HR, hazards ratio; CI, confidence interval; *PEX5*, Peroxisomal Biogenesis Factor 5; *TMEM135*, transmembrane protein 135.

Project. *TMEM135* rs567403 C>G has no significant finding (Figure S4A), while *PEX5* rs7969508 A>G is located in the H3K4Me1 region, which may have potential enhancer activity (Figure S4B).

Two independent SNPs and mRNA expression levels of the associated genes

To provide molecular support for the observed survival associations with, and predictions by, the genotypes, we




Figure 2 Kaplan-Meier survival curves of cutaneous melanoma-specific survival (CMSS): *TMEM135* rs567403 in dominant model in MDACC dataset (A), NHS/HPFS dataset (B), and the MDACC and NHS/HPFS combined dataset, (C) and *PEX5* rs7969508 in dominant model in the MDACC dataset (D), NHS/HPFS dataset (E), and the MDACC and NHS/HPFS combined dataset (F). Kaplan-Meier survival curves of the combined risk genotypes in CMSS: 0-1 risk genotypes group and 2 risk genotype group in MDACC (G), NHS/HPFS (H), and MDACC and NHS/HPFS combined datasets (I). 1Univariate analysis; 2Multivariate analysis. SNP, single nucleotide polymorphism; CM, cutaneous melanoma; *PEX5*, peroxisomal biogenesis factor 5; *TMEM135*, transmembrane protein 135; MDACC, The University of Texas MD Anderson Cancer Center; NHS, the Nurse Health Study; HPFS, the Health Professionals Follow-up Study.

further performed expression quantitative trait locus (eQTL) analysis to explore correlations between genotypes of the 2 independent SNPs and their associated mRNA expression levels in the publicly available RNA sequencing data of lymphoblastoid cell lines generated from 373 European descendants in the 1000 Genomes Project. The eQTL analysis revealed that rs567403 C>G was significantly correlated with elevated mRNA expression levels of *TMEM135* in an additive model ($P=0.003$,

Figure 3A), while rs7969508 A>G demonstrated a significant correlation with decreased mRNA expression levels of *PEX5* in all genetic models ($P=1.38 \times 10^{-10}$, $P=3.91 \times 10^{-10}$, and $P=0.0018$ for the additive, dominant, and recessive models, respectively; Figure 3B,C,D). We also performed an eQTL analysis using data from the Genotype-Tissue Expression (GTEx) Project V7.p2 (<http://www.gtexportal.org/home>). The results showed that rs7969508 A>G was correlated with significantly decreased




Figure 3 The expression quantitative trait loci (eQTL) analysis for genotypes of *PEX5* rs7969508 and *TMEM135* rs567403. (A) Correlation between *TMEM135* mRNA expression levels and rs567403 in 373 Europeans from the 1000 Genomes Project in an additive model. Correlation between *PEX5* mRNA expression and rs7969508 genotypes in 373 Europeans from the 1000 Genomes Project in additive (B), dominant (C), and recessive (D) models. Correlation between *PEX5* mRNA expression and rs7969508 in unexposed skin (E), sun-exposed skin (lower leg) (F), and whole blood cells (G) in GTEx. GTEx, Genotype-Tissue Expression Project; *PEX5*, peroxisomal biogenesis factor 5; *TMEM135*, transmembrane protein 135.

PEX5 mRNA expression in normal tissues from unexposed suprapubic skin ($P=2.6 \times 10^{-18}$), sun-exposed lower leg skin ($P=8.6 \times 10^{-23}$), and whole blood cells ($P=4.1 \times 10^{-14}$) (Figure 3E,F,G). These results were consistent with the findings of the 1000 Genomes Project. However, there were no significant correlations between rs567403 genotypes and mRNA expression levels of *TMEM135* in normal skin tissues from unexposed suprapubic skin ($P=0.260$), sun-exposed lower leg skin ($P=0.480$), or whole blood cells ($P=0.730$) (Figure S5) from the GTEx project.

Discussion

In the present study, we assessed the associations between SNPs in the peroxisome pathway-related genes and CM survival. We found that 2 independent and potentially functional SNPs (*TMEM135* rs567403 C>G and *PEX5* rs7969508 A>G) were independently or jointly associated

with survival in CM patients. Patients with a higher NRG score of these 2 genetic variants had a progressively worse survival. Importantly, the effect was consistent across most subgroups. Moreover, the *TMEM135* rs567403 risk G allele was found to be significantly correlated with increased mRNA expression levels of *TMEM135*, whereas the *PEX5* rs7969508 risk G allele was found to be significantly correlated with decreased mRNA expression levels of *PEX5*. These findings suggest that SNPs in peroxisomal pathway genes may play biological roles in the prognosis of CM, suggesting some biological plausibility of the survival-associated SNPs.

Peroxisome homeostasis is achieved by mediating the responses of peroxisome biogenesis and degradation to environmental conditions. By maintaining the integrity and number of organelles under different environmental stresses, pexophagy, as the process of selective autophagy, is essential for maintaining the stability of cellular

homeostasis, which is one of the mechanisms underlying peroxisome degradation (29). Peroxisomes are important sites of ROS production and degradation, and thus, play crucial roles in the development and progression of cancer (30). High levels of intracellular ROS can trigger cancer development by promoting pro-oncogenic mutations, and excessive ROS may contribute to progression of cancer cells (31). These may be the mechanisms through which peroxisomes affect cancer development and prognosis. However, no published studies have investigated the molecular mechanisms of the peroxisomes involved in CM survival.

TMEM135, located on chromosome 11q14.2, encodes transmembrane protein 135, which is one of peroxisomal proteins belonging to the Tim17 protein family. To date, the role of *TMEM135* in the biological processes of energy expenditure and the related fatty acid metabolism have remained unclear (32,33). Few studies have investigated the roles of *TMEM135* in cancer. One study that used sequencing analysis of independent cohorts for breast cancer found that *TMEM135* was a potential novel gene (34), and another study reported that rs11235127 near *TMEM135* had a statistically significant association with breast cancer risk (35). In prostate cancer patients, a novel fusion transcript in *TMEM135-CCDC67* was found to be associated with prostate cancer metastasis, recurrence, and prostate cancer-specific death after operation (36). A genome-wide linkage analysis of Spanish melanoma-prone families found a locus at 11q14.1-q14.3 with significant linkage evidence from multiple pedigrees, and the subregion contained *TMEM135* (37). In the present study, we found that the rs567403 G allele might up-regulate the expression of *TMEM135*, suggesting that *TMEM135* may play an oncogenic role in CM biology. However, additional experimental investigations are required to determine how *TMEM135* rs567403 C>G influences CMSS.

PEX5, located on chromosome 12p13.31, encodes the type-1 peroxisomal targeting signal (PTS1) receptor necessary for peroxisome biogenesis (38). Few studies have investigated the role of *PEX5* in cancer. One study suggested that under starvation conditions, *PEX5* depletion prevented the activation of autophagy (39), an important process in intracellular degradation that results in programmed cell death or the promotion of cell survival (40). Therefore, it is likely that the expression levels of *PEX5* may alter the processes of autophagy or cell death, which then affects the development and prognosis

of cancer. Studies have also reported that cell proliferation was inhibited after *PEX5* depletion in human hepatocellular carcinoma cells (16), and *PEX5* expression was significantly increased in colon carcinoma tissue compared with normal colon mucosa from 5 patients, as determined by northern blotting analysis (41). These findings suggest that *PEX5* may play an oncogenic role. However, in the present study we found that the *PEX5* rs7969508 G allele down-regulated the mRNA expression of *PEX5*, resulting in poor survival in CM patients. This suggests that *PEX5* may play a suppressor role in CM biology, which appears to disagree with reports about this gene in the literature, although we did not have additional experimental data to explain this finding.

The limitations of the present study are mainly related to the 2 GWAS datasets that were available to us. The sample sizes of the 2 GWAS datasets were insufficient, and some valuable clinical information, such as treatment and response rate, were not available for adjustment in the analysis; thus, the associations between these SNPs and CM survival should be further investigated in larger studies. Furthermore, the prognosis prediction model was built in non-Hispanic white populations of the United States, which may not be generalizable to other populations. Finally, additional functional experiments for these 2 independent SNPs should be performed to identify the molecular mechanisms underlying the observed survival association in CM patients.

Conclusions

In summary, we analyzed SNPs in the peroxisome pathway genes for their associations with CM survival using data from 2 published GWAS datasets, both of which had strict quality-control standards. The 2 novel SNPs we identified were predicted to have potential biological functions. Once our findings are replicated by other investigators, these genetic variants may serve as new biomarkers for predicting survival in CM patients.

Acknowledgments

The authors would like to thank Bingrong Zhou and Lingling Zhao for their technical assistance, and all participants and staff members of the Nurses Health Study and the Health Professionals Follow-Up Study for their valuable contributions, as well as the following state cancer registries for their support: AL, AZ, AR, CA, CO, CT,

DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The authors also thank the Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital as the home of the NHS. The authors assume full responsibility for the analysis and interpretation of these data. We also thank the Johns Hopkins University Center for Inherited Disease Research for conducting high-throughput genotyping for our study. We also thank all of the investigators and funding agencies that enabled the deposition of the data in dbGaP used here (dbGaP Study Accession: phs000187.v1.p1).

Funding: This work was partly supported by NIH/NCI R01CA100264, 2P50CA093459, R01CA133996, R01CA49449, P01CA87969, UM1CA186107, UM1CA167552, The University of Texas MD Anderson Cancer Center Various Donors Melanoma and Skin Cancers Priority Program Fund, the Miriam and Jim Mulva Research Fund, the McCarthy Skin Cancer Research Fund, and the Marit Peterson Fund for Melanoma Research.

Footnote

Reporting Checklist: The authors have completed the TRIPOD reporting checklist. Available at <http://dx.doi.org/10.21037/atm-20-2117>

Data Sharing Statement: Available at <http://dx.doi.org/10.21037/atm-20-2117>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/atm-20-2117>). Dr. Wang reports grants from The First hospital of Jilin University, outside the submitted work. Dr. Wei reports grants from Duke Cancer Institute, outside the submitted work. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Informed consent was taken from all the patients, and the access to the datasets was approved by the Institutional Review Boards of the MDACC (No. LAB03-0048), Brigham and Women's Hospital (No. 2007-P-000616), and Harvard T.H. Chan School of Public Health (No. 2007-P-000616) and

conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Rogers HW, Weinstock MA, Feldman SR, et al. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. *JAMA Dermatol* 2015;151:1081-6.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin* 2019;69:7-34.
3. Abbas O, Miller DD, Bhawan J. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. *Am J Dermatopathol* 2014;36:363-79.
4. Berwick M, Buller DB, Cust A, et al. Melanoma Epidemiology and Prevention. *Cancer Treat Res* 2016;167:17-49.
5. Pejnova S, Dzokic G, Tudzarova-Gjorgova S, et al. Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma. *Pril (Makedon Akad Nauk Umet Odd Med Nauki)* 2016;37:89-97.
6. Dai W, Liu H, Xu X, et al. Genetic variants in ELOVL2 and HSD17B12 predict melanoma-specific survival. *Int J Cancer* 2019;145:2619-28.
7. Sud A, Kinnersley B, Houlston RS. Genome-wide association studies of cancer: current insights and future perspectives. *Nat Rev Cancer* 2017;17:692-704.
8. Lodhi IJ, Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular signaling. *Cell Metab* 2014;19:380-92.
9. Van Veldhoven PP. Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism. *J Lipid Res* 2010;51:2863-95.
10. Odendall C, Dixit E, Stavru F, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. *Nat Immunol* 2014;15:717-26.

11. Dixit E, Boulant S, Zhang Y, et al. Peroxisomes are signaling platforms for antiviral innate immunity. *Cell* 2010;141:668-81.
12. Nordgren M, Fransen M. Peroxisomal metabolism and oxidative stress. *Biochimie* 2014;98:56-62.
13. Dorninger F, Wiesinger C, Braverman NE, et al. Ether lipid deficiency does not cause neutropenia or leukopenia in mice and men. *Cell Metab* 2015;21:650-1.
14. Puri P, Wiest MM, Cheung O, et al. The plasma lipidomic signature of nonalcoholic steatohepatitis. *Hepatology* 2009;50:1827-38.
15. Cipolla CM, Lodhi IJ. Peroxisomal Dysfunction in Age-Related Diseases. *Trends Endocrinol Metab* 2017;28:297-308.
16. Cai M, Sun X, Wang W, et al. Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells. *Cancer Lett* 2018;421:82-93.
17. Shukla N, Adhya AK, Rath J. Expression of Alpha - Methylacyl - Coenzyme A Racemase (AMACR) in Colorectal Neoplasia. *J Clin Diagn Res* 2017;11:EC35-8.
18. Zhou M, Chinnaiyan AM, Kleer CG, et al. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. *Am J Surg Pathol* 2002;26:926-31.
19. Honma I, Torigoe T, Hirohashi Y, et al. Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. *J Transl Med* 2009;7:103.
20. Amos CI, Wang LE, Lee JE, et al. Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. *Hum Mol Genet* 2011;20:5012-23.
21. Song F, Qureshi AA, Zhang J, et al. Exonuclease 1 (EXO1) gene variation and melanoma risk. *DNA Repair (Amst)* 2012;11:304-9.
22. Li Y, Willer CJ, Ding J, et al. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol* 2010;34:816-34.
23. Lappalainen T, Sammeth M, Friedlander MR, et al. Transcriptome and genome sequencing uncovers functional variation in humans. *Nature* 2013;501:506-11.
24. Wakefield J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. *Am J Hum Genet* 2007;81:208-27.
25. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res* 2012;40:D930-4.
26. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263-5.
27. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 2010;26:2336-7.
28. Chambless LE, Diao G. Estimation of time-dependent area under the ROC curve for long-term risk prediction. *Stat Med* 2006;25:3474-86.
29. Walker CL, Pomatto LCD, Tripathi DN, et al. Redox Regulation of Homeostasis and Proteostasis in Peroxisomes. *Physiol Rev* 2018;98:89-115.
30. Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. *Cell Mol Life Sci* 2009;66:3663-73.
31. Tubbs A, Nussenzweig A. Endogenous DNA Damage as a Source of Genomic Instability in Cancer. *Cell* 2017;168:644-56.
32. Žárský V, Dolezal P. Evolution of the Tim17 protein family. *Biol Direct* 2016;11:54.
33. Exil VJ, Silva Avila D, Benedetto A, et al. Stressed-induced TMEM135 protein is part of a conserved genetic network involved in fat storage and longevity regulation in *Caenorhabditis elegans*. *PLoS One* 2010;5:e14228.
34. Natrajan R, Mackay A, Lambros MB, et al. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. *J Pathol* 2012;227:29-41.
35. Teraoka SN, Bernstein JL, Reiner AS, et al. Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study. *Breast Cancer Res* 2011;13:R114.
36. Yu YP, Ding Y, Chen Z, et al. Novel fusion transcripts associate with progressive prostate cancer. *Am J Pathol* 2014;184:2840-9.
37. Potrony M, Puig-Butille JA, Farnham JM, et al. Genome-wide linkage analysis in Spanish melanoma-prone families identifies a new familial melanoma susceptibility locus at 11q. *Eur J Hum Genet* 2018;26:1188-93.
38. Dodt G, Gould SJ. Multiple PEX genes are required for proper subcellular distribution and stability of Pex5p, the PTS1 receptor: evidence that PTS1 protein import is mediated by a cycling receptor. *J Cell Biol* 1996;135:1763-74.
39. Eun SY, Lee JN, Nam IK, et al. PEX5 regulates autophagy via the mTORC1-TFEB axis during starvation. *Exp Mol Med* 2018;50:1-12.

40. Singletary K, Milner J. Diet, autophagy, and cancer: a review. *Cancer Epidemiol Biomarkers Prev* 2008; 17:1596-610.

41. Lauer C, Volkl A, Riedl S, et al. Impairment of peroxisomal biogenesis in human colon carcinoma. *Carcinogenesis* 1999;20:985-9.

Cite this article as: Wang H, Liu H, Dai W, Luo S, Amos CI, Lee JE, Li X, Yue Y, Nan H, Wei Q. Association of genetic variants of TMEM135 and PEX5 in the peroxisome pathway with cutaneous melanoma-specific survival. *Ann Transl Med* 2021;9(5):396. doi: 10.21037/atm-20-2117